Table Info

Table 4.

Predicted and observed clearance values in children

Medicines	Age	Observed clearance (mL/min)		Predicted clearance (mL/min)		Ratio = predicted/observed
Medicines	Age	IV	Oral	IV	Oral	IV	Oral
Midazolam	Adult	323	763	NA	NA	NA	NA
	Preterm	1.8	2.9	2.0	5.2	1.10	1.80
	0.5–2 years	52	286	36	85	0.69	0.30
	5.5–6 years	159	585	114	270	0.72	0.46
Famotidine	Adult	463	1,030	NA	NA	NA	NA
	11–15 years	400	718	360	800	0.90	1.11
	0–1 year	55	131	66	147	1.20	1.12
Voriconazole	Adult	254	323	NA	NA	NA	NA
	2–<6 years	102	232	92	117	0.90	0.50
	6–<12 years	171	279	137	174	0.80	0.62
Diclofenac	Adult	263	499	NA	NA	NA	NA
Diclofenac	1–12 years	153	218	103	173	0.67	0.79
Cyclosporine	Adult	317	1,683	NA	NA	NA	NA
Cyclosporine	1.1–2.5 years	113	518	57	305	0.51	0.59
Cefetamet	Adult	155	399	NA	NA	NA	NA
	3–7 years	50	230	54	138	1.07	0.60
	>7–12 years	79	393	94	242	1.19	0.62
	3.5–17 months	18	48	21	54	1.16	1.12
Zidovudine	Adult	1,377	1,832	NA	NA	NA	NA
	Term < 14 days	22	32	28	37	1.25	1.15
	Term > 14 days	76	85	76	101	0.99	1.18
Azithromycin	Adult	817	1,910	NA	NA	NA	NA
	0.5–2 years	166	606	118	306	0.71	0.50
	>2–5 years	280	749	214	480	0.76	0.64
	7–12 years	624	1,191	527	1,172	0.84	0.98
Busulfan	Adult	175	240	NA	NA	NA	NA
Busulfan	1.4–6 years	57	99	58	79	1.01	0.80
Cimetidine	Adult	495	840	NA	NA	NA	NA
Cimetidine	4–13 years	302	559	236	400	0.78	0.71
Digoxin	Adult	192	262	NA	NA	NA	NA
Digoxin	Infants	39	55	8	11	0.21	0.20
Clonidine	Adult	260	292	NA	NA	NA	NA
Clonidine	3–10 years	85	155	102	114	1.20	0.74
Ranitidine	Adult	677	1,485	NA	NA	NA	NA
Ranitidine	3.5–16 years	568	1,183	526	1,154	0.93	0.98
Ketoprofen	Adult	83	90	NA	NA	NA	NA
	7–93 months	23	30	32	35	1.41	1.17
	0.5–2 years	12	15	12	13	0.99	0.86
	>2–7 years	22	32	31	34	1.42	1.06
Itraconazole	Adult	337	1,762	NA	NA	NA	NA
	0.5–2 years	173	541	44	219	0.25	0.40
	>2–5 years	160	465	123	563	0.76	1.21
	>5–12 years	298	991	173	787	0.58	0.79

For clearances same references as of absolute bioavailability. IV: intravenous; NA: not available

Declarations

Author contributions

IM: Conceptualization, Data curation, Writing—original draft.

Conflicts of interest

The author has no conflicts of interest.

Ethical approval

Since this study analyzed secondary data, ethical approval is not required.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Requests for accessing the datasets should be directed to Iftekhar Mahmood (Iftekharmahmood@aol.com).

Funding

Not applicable.

Copyright

References

Shargel L, Yu A. Bioavailability and bioequivalence. In: Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Norfolk (CT): Appleton & Lange; 1993. pp. 193.

Mahmood I. Developmental pharmacology: Impact on pharmacokinetics and pharmacodynamics of drugs. In: Mahmood I, Burckart G, editors. Pediatric Pharmacology and Pharmacokinetics. Cham: Adis; 2016. pp. 23–44.

Gibaldi M, Perrier D. Clearance Concept. In: Pharmacokinetics. 2nd ed. Mercell Dekker; 1982. pp. 319.

Mahmood, I. Prediction of Drug Clearance in Preterm and Term Neonates by Minimal Physiologically Based Pharmacokinetic Model and Allometry: A Comparison with Whole BODY Physiologically Based Pharmacokinetic Model. Med Res Arch. 2023;11:1–10. [DOI]

Mahmood I. Prediction of Clearance, Volume of distribution, and Half-life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach. Eur J Drug Metab Pharmacokinet. 2017;42:601–10. [DOI] [PubMed]

Mahmood I, Tegenge MA. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents. J Clin Pharmacol. 2019;59:189–7. [DOI] [PubMed]

Nicolas JM, Bouzom F, Hugues C, Ungell AL. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. Biopharm Drug Dispos. 2017;38:209–30. [DOI] [PubMed] [PMC]

Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983;16:43S–9S. [DOI] [PubMed] [PMC]

de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol. 2002;53:390–2. [DOI] [PubMed] [PMC]

10.

de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther. 2001;70:525–31. [DOI] [PubMed]

11.

Reed MD, Rodarte A, Blumer JL, Khoo KC, Akbari B, Pou S, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol. 2001;41:1359–69. [DOI] [PubMed]

12.

Payne K, Mattheyse FJ, Liebenberg D, Dawes T. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol. 1989;37:267–72. [DOI] [PubMed]

13.

Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, et al. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm Drug Dispos. 1987;8:549–60. [DOI] [PubMed]

14.

Nagita A, Manago M, Aoki S, Mino M, Suzuki K, Ashida K. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit. 1994;16:444–9. [DOI] [PubMed]

15.

Wenning LA, Murphy MG, James LP, Blumer JL, Marshall JD, Baier J, et al. Pharmacokinetics of famotidine in infants. Clin Pharmacokinet. 2005;44:395–406. [DOI] [PubMed]

16.

Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906–15. [DOI] [PubMed] [PMC]

17.

Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54:4116–23. [DOI] [PubMed] [PMC]

18.

Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol. 1979;16:405–10. [DOI] [PubMed]

19.

Korpela R, Olkkola KT. Pharmacokinetics of intravenous diclofenac sodium in children. Eur J Clin Pharmacol. 1990;38:293–5. [DOI] [PubMed]

20.

Standing JF, Howard RF, Johnson A, Savage I, Wong IC. Population pharmacokinetics of oral diclofenac for acute pain in children. Br J Clin Pharmacol. 2008;66:846–53. [DOI] [PubMed] [PMC]

21.

Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995;57:485–91. [DOI] [PubMed]

22.

Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol. 1991;5:1–4. [DOI] [PubMed]

23.

Blouin RA, Kneer J, Stoeckel K. Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother. 1989;33:291–6. [DOI] [PubMed] [PMC]

24.

Hayton WL, Walstad RA, Thurmann-Nielsen E, Kufaas T, Kneer J, Ambros RJ, et al. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children. Antimicrob Agents Chemother. 1991;35:720–5. [DOI] [PubMed] [PMC]

25.

Hayton WL, Kneer J, de Groot R, Stoeckel K. Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants. Antimicrob Agents Chemother. 1996;40:567–74. [DOI] [PubMed] [PMC]

26.

Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, et al. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother. 1995;39:2732–7. [DOI] [PubMed] [PMC]

27.

Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993;122:137–44. [DOI] [PubMed]

28.

Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005;49:5013–7. [DOI] [PubMed] [PMC]

29.

Jacobs RF, Maples HD, Aranda JV, Espinoza GM, Knirsch C, Chandra R, et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J. 2005;24:34–9. [DOI] [PubMed]

30.

Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother. 1995;39:1875–7. [DOI] [PubMed] [PMC]

31.

Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother. 1993;37:314–6. [DOI] [PubMed] [PMC]

32.

Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A, et al. Busulfan bioavailability. Blood. 1994;84:2144–50. [PubMed]

33.

Somogyi A, Rohner HG, Gugler R. Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet. 1980;5:84–94. [DOI] [PubMed]

34.

Somogyi A, Becker M, Gugler R. Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr. 1985;144:72–6. [DOI] [PubMed]

35.

Hager WD, Mayersohn M, Graves PE. Digoxin bioavailability during quinidine administration. Clin Pharmacol Ther. 1981;30:594–9. [DOI] [PubMed]

36.

Wettrell G, Andersson KE. Absorption of digoxin in infants. Eur J Clin Pharmacol. 1975;9:49–55. [DOI] [PubMed]

37.

Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man-evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol. 1981;12:653–8. [DOI] [PubMed] [PMC]

38.

Larsson P, Nordlinder A, Bergendahl HT, Lönnqvist PA, Eksborg S, Almenrader N, et al. Oral bioavailability of clonidine in children. Paediatr Anaesth. 2011;21:335–40. [DOI] [PubMed]

39.

Chau NP, Zech PY, Pozet N, Hadj-Aissa A. Ranitidine kinetics in normal subjects. Clin Pharmacol Ther. 1982;31:770–4. [DOI] [PubMed]

40.

Blumer JL, Rothstein FC, Kaplan BS, Yamashita TS, Eshelman FN, Myers CM, et al. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. J Pediatr. 1985;107:301–6. [DOI] [PubMed]

41.

Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs. 2010;12:313–29. [DOI] [PubMed]

42.

Kokki H, Karvinen M, Suhonen P. Pharmacokinetics of intravenous and rectal ketoprofen in young children. Clin Pharmacokinet. 2003;42:373–9. [DOI] [PubMed]

43.

Kokki H, Tuomilehto H, Karvinen M. Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. Eur J Clin Pharmacol. 2001;57:643–7. [DOI] [PubMed]

44.

Kokki H, Le Liboux A, Jekunen A, Montay G, Heikkinen M. Pharmacokinetics of ketoprofen syrup in small children. J Clin Pharmacol. 2000;40:354–9. [DOI] [PubMed]

45.

Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32:1310–3. [DOI] [PubMed] [PMC]

46.

Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother. 2006;50:4096–102. [DOI] [PubMed] [PMC]

47.

de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother. 1998;42:404–8. [DOI] [PubMed] [PMC]

48.

Abdel-Rahman SM, Jacobs RF, Massarella J, Kauffman RE, Bradley JS, Kimko HC, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-β-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother. 2007;51:2668–73. [DOI] [PubMed] [PMC]

49.

Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59:691–704. [DOI] [PubMed] [PMC]

50.

Scheline RR. Drug metabolism by intestinal microorganisms. J Pharm Sci. 1968;57:2021–37. [DOI] [PubMed]

51.

Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm. 2008;363:1–25. [DOI] [PubMed]

52.

Tralau T, Sowada J, Luch A. Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology? Expert Opin Drug Metab Toxicol. 2015;11:411–25. [DOI] [PubMed]

53.

Linday L, Dobkin JF, Wang TC, Butler VP Jr, Saha JR, Lindenbaum J. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics. 1987;79:544–8. [PubMed]

54.

Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60:14–24. [PubMed]

55.

Mahmood I. Prediction of oral pharmacokinetic parameters in humans. In: Interspecies Pharmacokinetic Scaling. Rockville (MD): Pine House Publishers; 2005. pp. 144–67.